NCT07320300

Brief Summary

clinical evaluation of the prevalence and severity of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
19mo left

Started Jan 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
Jan 2026Dec 2027

First Submitted

Initial submission to the registry

November 22, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 6, 2026

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

January 6, 2026

Status Verified

December 1, 2025

Enrollment Period

1.8 years

First QC Date

November 22, 2025

Last Update Submit

December 27, 2025

Conditions

Cognition - Other

Outcome Measures

Primary Outcomes (2)

  • the prevalence of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department

    clinical evaluation of the prevalence of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry departmen

    baseline

  • prevalence estimates of PSCI within the stroke population admitted to a tertiary hospital.

    baseline

Interventions

Cognitive assessment: Montreal Cognitive Assessment (MoCA), Cognitive Assessment for Stroke patients, Oxford cognitive screening, Trail Making Test B, Digit Span-Backward, verbal fluency, Clinical DemOTHER

Follow-up: for cognitive and functional reassessment

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

egyptian population

You may qualify if:

  • Patients of both sexes, aged 18- 60 years, with a history of first stroke within 3 months of admission, all types of stroke confirmed by imaging (ischemia, parenchymal haemorrhage, subarachnoid haemorrhage, venous stroke)

You may not qualify if:

  • Age above 60 years, refusal to participate in the study, pre-existing dementia or significant psychiatric illness, severe aphasia or communication deficits precluding cognitive testing or severe comorbid condition limiting follow-ups, systemic diseases that are known to affect the central nervous system, such as (thyroid dysfunction, chronic infections, or system failure like liver or renal failure), significant sensory impairment (deafness and blindness), history of malignancy and those who have had neurosurgical procedures or severe head trauma at any time before a stroke.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Mental Status and Dementia Tests

Intervention Hierarchy (Ancestors)

Neuropsychological TestsPsychological TestsBehavioral Disciplines and Activities

Central Study Contacts

kamal eldin Mohamed

CONTACT

0201003983057Kamal.17289724@med.aun.edu.eg

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident doctor

Study Record Dates

First Submitted

November 22, 2025

First Posted

January 6, 2026

Study Start

January 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

January 6, 2026

Record last verified: 2025-12